Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
bronchospasms; This spontaneous report was received from a physician and refers to a 90-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (exact dose, route of administration, anatomical location, lot # ,and expiration date were not reported) for pneumococcal disease prevention (prophylaxis). On an unknown date in 2025, reported as two months ago, the patient experienced bronchospasms and went to emergency room (ER). At the reporting time, the outcome of bronchospasms was unknown. The causal relationship between the event of bronchospasms and Pneumococcal 21-valent Conjugate (CAPVAXIVE) vaccine was not provided.